Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
Status:
Completed
Trial end date:
2017-09-06
Target enrollment:
Participant gender:
Summary
Cantharidin is cited in the dermatology and pediatric literature as a valuable treatment
option. Treatment is often available in private practice offices, where a prescribing
physician may offer a non-FDA approved treatment on an individualized basis. The situation is
different in many hospital and academic settings, such as our own for example, where the
formulary is defined through a FDA-approved indication. The absence of an indication
precludes its addition to many hospital formularies, thus limiting the options available to a
prescribing physician and denying patient access to a treatment offered in the private
practice setting. An indication and formulary status require controlled clinical trials on
the safety and efficacy of cantharidin in MC. The objective of this trial is to see if this
commercially-viable cantharidin formulation has a comparable safety and efficacy profile as
formulations previously studied under conditions which most closely match the what has been
historically done in the clinic.